Furthermore, the development of ghrelin antagonists, including AG-blocking agents and novel GOAT inhibitors, presents a promising avenue for combating obesity by modulating ghrelin activity and its downstream metabolic effects [117]. This evidence concerns the gene MBOAT4 and obesity disorder.